Company Description
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation.
Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer’s disease, as well as is in Phase 2 clinical trials to treat Parkinson’s disease dementia and Dementia with Lewy bodies.
The company’s product pipeline includes ATH-1020, an orally available brain-penetrant small molecule designed to enhance the HGF/MET system that is in Phase 1 clinical trials to treat neuropathic pain and neurodegenerative diseases; and ATH-1105, an oral small molecule drug candidate, which is a preclinical model for the treatment of Amyotrophic Lateral Sclerosis.
In addition, it has a license agreement with Washington State University to offer for sale products covered by certain licensed patents, including dihexa, the chemical compound into which fosgonimeton metabolizes following administration; and collaboration and grant agreement with National Institutes of Health Grant to support ACT-AD Phase 2 clinical trial for fosgonimeton.
The company was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019.
Athira Pharma, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.
| Country | United States |
| Founded | 2011 |
| IPO Date | Sep 18, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 67 |
| CEO | Mark Litton |
Contact Details
Address: 18706 North Creek Parkway, Suite 104 Bothell, Washington 98011 United States | |
| Phone | 425 620 8501 |
| Website | athira.com |
Stock Details
| Ticker Symbol | ATHA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $17.00 |
| CIK Code | 0001620463 |
| CUSIP Number | 04746L104 |
| ISIN Number | US04746L1044 |
| Employer ID | 45-3368487 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Mark J. Litton M.B.A., Ph.D. | President, Chief Executive Officer and Director |
| Robert Renninger | Vice President of Finance, Principal Financial Officer and Principal Accounting Officer |
| Dr. Kevin Church Ph.D. | Chief Scientific Officer |
| Julie Rathbun | Head of Investor Relations |
| Mark F. Worthington J.D. | General Counsel, Chief Compliance Officer and Corporate Secretary |
| Dr. Javier San Martin M.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 31, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Oct 28, 2024 | EFFECT | Notice of Effectiveness |
| Oct 21, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| Oct 18, 2024 | 8-K | Current Report |
| Oct 7, 2024 | 8-K | Current Report |
| Sep 17, 2024 | 8-K | Current Report |
| Sep 5, 2024 | 144 | Filing |
| Sep 3, 2024 | 8-K | Current Report |
| Aug 9, 2024 | 10-Q/A | [Amend] Quarterly report |
| Aug 1, 2024 | 10-Q | Quarterly Report |